certolizumab IBD
Selected indexed studies
- A comprehensive review and update on Crohn's disease. (Dis Mon, 2018) [PMID:28826742]
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. (Gastroenterology, 2022) [PMID:34757139]
- Uveitis and spondyloarthropathies. (Best Pract Res Clin Rheumatol, 2017) [PMID:30509444]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. (2022) pubmed
- A comprehensive review and update on Crohn's disease. (2018) pubmed
- Uveitis and spondyloarthropathies. (2017) pubmed
- [IBD: Crohn's disease]. (2016) pubmed
- Biologic agents for IBD: practical insights. (2015) pubmed
- Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials. (2024) pubmed
- Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. (2024) pubmed
- Therapeutic Drug Monitoring of Certolizumab Pegol: Can Real-World Data Translate to Clinical Practice? (2021) pubmed
- Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment. (2025) pubmed
- Certolizumab pegol for induction of remission in Crohn's disease. (2019) pubmed